Targeting the PKCβII-ACSL4 axis augments the efficacy of ICI therapy.[191] The further clinical study finds that ACSL4 expression is highly associated with T cell-related immune score and is a potential predictor for anti-PD1 immunotherapy response.[191] Among melanoma patients, those with high ACSL4 expression have better sensitivity towards immunotherapy.[187] Simultaneously, ACSL4 is regarded as an immune-related prognostic biomarker in cholangiocarcinoma.[192] However, how ACSL4 influences T cell-involving antitumoral effects and underlying cell communications needs further investigation. The gene discussed is ACSL4; the disease is melanoma.